Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18 and 49 years.~* Available for follow-up throughout the study period (approximately 120 days).~* Ability to understand and sign the informed consent form (IC).~* HIV serology negative~* Absence of helminth infections in general (nematodes, cestodes and trematodes, among which Schistosoma mansoni) at the inclusion in the study.~* Patients who has not chronic use or have not used in the past 45 days any medication, except trifling as nasal saline and vitamins.~* Be in good health without significant medical history.~* Screening physical examination without clinical significant abnormalities.~* Screening laboratory tests without significant abnormalities according to normal standards and the evaluation of investigators.~* Additional criteria for females of childbearing potential: Negative pregnancy test at screening; consistent use of contraceptive methods (male or female condom, diaphragm, IUD and oral contraceptives or patches).~Exclusion Criteria:~* Women who are pregnant or breastfeeding.~* Use of cytotoxic or immunosuppressive drugs in the last six months, except for spray nasal corticosteroids for allergic rhinitis or topical corticosteroids for uncomplicated dermatitis.~* Immunoglobulin use 60 days prior to vaccination.~* Use of any type of vaccine 30 days prior to vaccination.~* Plan to receive any other vaccine during the period of participation in the study (four months)~* Use any type of investigational medication in a period of 30 days prior to vaccination~* Use of allergy shots with antigens within 14 days prior to vaccination.~* Psychiatric illness that hinders adherence to the protocol, such as psychosis, obsessive-compulsive neurosis, bipolar disorder treatment, diseases that require treatment with lithium, and suicide thoughts in the last 5 years prior to inclusion.~* Presence of neurological disease, liver disease or kidney disease (diseases which have led to hospitalization or prolonged treatment).~* History of sickle cell anemia.~* Asplenia (no spleen or its removal).~* History of alcohol use/abuse (CAGE criterion) or illicit drugs.~* Blood pressure above 140/90 mmHg at screening or hypertension requiring drug treatment.~* Coagulopathy diagnosed by a doctor or report of capillary fragility (eg, bruising, bleeding, etc.) after injections or blood sampling.~* Active malignancy (eg, any type of cancer) or treated so it may relapse during the study.~* History of allergy to vaccines containing adjuvants composed of lipids (GLA or MPL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- single arm (Type: EXPERIMENTAL): 3 doses of the vaccine, on days 0, 30 and 60.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete